CompletedPhase 2

GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations

Exploration of the Physiological Effect of GLP-1 in Obese Adults Diagnosed With Obesity Causing Genetic Mutations

Lead sponsor

University of Copenhagen

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Hypothalamic / syndromic obesity, Obesity / overweight

Eligibility highlights

•BMI ≥28•Healthy volunteers

Primary endpoint

•Insulin levels in reponse to GLP-1 RA treatment in obese genetic mutation

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02082496

Org study IDMC4R-2014

Timeline

Milestones

Study first posted2014-03-10estimated

Last update posted2020-05-13actual

Study start2014-06actual (month precision)

Primary completion2016-04actual (month precision)

Study completion2019-04actual (month precision)

Assets

Investigational agents

Liraglutide

Who this study enrolls

Hypothalamic / syndromic obesityObesity / overweight

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•BMI above 28 (kg/m2)

•age 18-65 years

•otherwise healthy

Exclusion criteria

•pregnancy or breastfeeding

•Type 2 Diabetes

•suffering from severe medical conditions

Recruitment for this study finished November 2015

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint/low confidence

Difference in insulin levels in reponse to GLP-1 RA treatment in obese genetic mutation carriers vs obese controls

Time frame:4 months intervention

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.